• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.01% Nasdaq Up0.26%

    Baxter International Inc. (BAX)

    37.88 Down 0.16(0.42%) Nov 25, 4:01PM EST
    ProfileGet Profile for:
    Baxter International Inc.
    One Baxter Parkway
    Deerfield, IL 60015
    United States - Map
    Phone: 224-948-2000
    Website: http://www.baxter.com

    Index Membership:N/A
    Industry:Medical Instruments & Supplies
    Full Time Employees:66,000

    Business Summary 

    Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company’s BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; and biosurgery products. The Medical Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics; and products and services related to pharmacy compounding, drug formulation and packaging technologies, as well as to treat renal disease, irreversible kidney failures, and other renal therapies. This segment also offers products for peritoneal dialysis, in-center and home hemodialysis, continuous renal replacement therapy, and other dialysis services. It markets its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy to hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, clinical and medical research laboratories, and patients. The company operates in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Latin America, and Canada. It has collaboration with Merrimack Pharmaceuticals, Inc. to develop and commercialize MM-398 injection; CTI BioPharma Corp. to develop and commercialize pacritinib; Coherus Biosciences, Inc. and Momenta Pharmaceuticals, Inc. to develop and commercialize biosimilars; JW Holdings Corporation for parenteral nutritional products; and Onconova Therapeutics, Inc. for rigosertib anti-cancer compound. The company was founded in 1931 and is based in Deerfield, Illinois.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Baxter International Inc.

    Corporate Governance 
    Baxter International Inc.’s ISS Governance QuickScore as of Nov 1, 2015 is 10. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 10; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Robert L. Parkinson Jr., 64
    Chairman, Chief Exec. Officer and Pres
    Mr. David P. Scharf , 47
    Corp. VP, Gen. Counsel and Corp. Sec.
    Ms. Jeanne K. Mason Ph.D., 59
    Corp. VP of HR
    Mr. James K. Saccaro , 42
    Chief Financial Officer and Corp. VP
    Mr. Timothy P. Lawrence ,
    Corp. VP of Operations
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders